3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Motor Activity
20
Polycystic Ovary Syndrome
10
Prostatic Neoplasms
7
Breast Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
4
Insulin Resistance
3
Lung Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Cardiotoxicity
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Primary Dysautonomias
1
Pediatric Brain Tumor
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Follicular
1
Lupus Erythematosus, Systemic
1
Inflammation
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Diabetes Mellitus, Type 1
1
Chemotherapy-Related Cognitive Impairment
1
Cardiovascular Diseases
1
Interventions
Gemcitabine
15
Mitomycin
10
Docetaxel
7
BCG Vaccine
7
Cystoscopy
4
tislelizumab
3
durvalumab
3
Radiotherapy
3
Epirubicin
3
disitamab vedotin
2
avelumab
2
Hyaluronic Acid
2
tremelimumab
1
toripalimab
1
pemigatinib
1
pembrolizumab
1
monalizumab
1
lornoxicam
1
erdafitinib
1
enzalutamide
1
chondroitin sulfate, sodium hyaluronate drug combination
1
bicalutamide
1
VPM1002 recombinant BCG vaccine
1
Urine Specimen Collection
1
Ty21a typhoid vaccine
1
Transurethral Resection of Bladder
1
Therapeutics
1
Surveys and Questionnaires
1
Sugars
1
Saline Solution
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Non-Muscle Invasive Bladder Neoplasms
×
High-Intensity Interval Training
×
Clear all
NCT04593862
2024-09-19
BRAVE
University of Alberta
Phase 2
Completed
25 enrolled